bioTheranostics’ Breast Cancer Index℠ Genomic Test Selected as Finalist in 27th Annual CONNECT Most Innovative New Product Awards

SAN DIEGO--()--bioTheranostics, Inc., a leading genomic solutions provider for cancer, today announced that its Breast Cancer IndexSM molecular test has been selected as a finalist in the Life Sciences—Diagnostics & Research Tools category for the 2014 Most Innovative New Product Awards, sponsored by CONNECT. CONNECT, a regional program that catalyzes the creation of innovative technology and life sciences products in San Diego County, continues its 27-year tradition of honoring San Diego's leaders of innovation and groundbreaking new products with the annual award.

The Breast Cancer Index is a unique molecular genomic test based on its ability to inform decisions about extended endocrine treatment for estrogen receptor-positive (ER+) breast cancer patients. It is the only test on the market that predicts which patients have a high vs. low likelihood of benefitting from extended endocrine therapy and quantifies the risk of late (>5 years post-diagnosis) breast cancer recurrence. Development of the test stems from more than 10 years of research and clinical validation designed to investigate and discover biomarkers that track the multiple cellular signaling pathways that can lead to endocrine response and breast cancer recurrence. The result is a breakthrough test that helps oncologists and patients navigate the difficult trade-off between wanting to take steps to prevent recurrence of their disease, and facing significant side effects and safety challenges related to extended endocrine therapy.

“Being selected as a finalist in the CONNECT Most Innovative New Product Awards is a tremendous honor for bioTheranostics, and a testament to the hard work and dedication of our exceptional scientific and commercial teams,” said Nicolas Barthelemy, President and CEO of bioTheranostics. “The Breast Cancer Index provides patient-specific information that facilitates selection of patients who are likely to benefit from extended adjuvant endocrine therapy, thus potentially sparing those unlikely to benefit from unnecessary adverse events and toxicities associated with the treatment. For patients identified as at high-risk of recurrence over 5–10 years, the test can help clinicians establish appropriate follow up and emphasize the importance of compliance with treatment.”

The CONNECT Most Innovative New Product Awards ceremony, to be held at the Hyatt Regency La Jolla at Aventine on December 4, will honor product innovation in the following eight categories: Aerospace & Security Technologies, Communications & IT, Diagnostics & Research Tools, Mobile Apps, Pharmaceutical Drugs & Medical Devices, Software, Sport & Active Lifestyle Technologies and Sustainability.

“For 27 years, CONNECT has been hosting the Most Innovative New Product Awards, and each year the entrants just keep getting better—this is one of the most competitive fields we’ve seen yet,” said Greg McKee, CEO of CONNECT. “Annually, through the Most Innovative New Product Awards, CONNECT proudly presents to the community the innovations and ground-breaking products being developed in San Diego.”

The 2014 Most Innovative New Product Awards received generous support from lead sponsors Ardea Biosciences and Cubic, as well as supporting sponsors Barney & Barney, Cox, CBRE, D&K Engineering, Kaiser Permanente, Knobbe Martens, Merck, Nextivity, Pfizer, PricewaterhouseCoopers, Procopio, Qualcomm and San Diego State University. For the complete list of winners and other information, visit the Most Innovative New Product Awards website.

About bioTheranostics

bioTheranostics, Inc., is a leader in helping physicians improve the care and management of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients. The company’s Breast Cancer IndexSM helps oncologists make difficult decisions about extended endocrine therapy for estrogen receptor-positive breast cancer patients based on its unique ability to predict risk of late disease recurrence and identify which patients are likely to benefit from continuing therapy beyond five years. Its bioT3 Metastatic Cancer Solution combines accurate diagnosis with comprehensive biomarker information that allows improved treatment for metastatic cancer patients. bioTheranostics, a bioMérieux company, is based in San Diego. Learn more at www.biotheranostics.com.

About CONNECT

CONNECT is a regional program that catalyzes the creation of innovative technology and life sciences products in San Diego County by creating an environment in which inventors and entrepreneurs have access to the resources they need for success. Since 1985, CONNECT has assisted in the formation and development of more than 3,000 companies and is now widely regarded as one of the world’s most successful organizations linking inventors and entrepreneurs with the resources they need for commercialization of innovative products. As a result, the program has been modeled in more than 50 regions around the world—most recently in New York City, Bogotá, Colombia and Saudi Arabia. To learn more about CONNECT, please visit www.connect.org or call 858.964.1300.

Contacts

Sullivan & Associates
Barbara Sullivan, 714/374–6174
bsullivan@sullivanpr.com

Release Summary

bioTheranostics, Inc. today announced that its Breast Cancer Index molecular test has been selected as a finalist for the 2014 Most Innovative New Product Award, sponsored by CONNECT.

Contacts

Sullivan & Associates
Barbara Sullivan, 714/374–6174
bsullivan@sullivanpr.com